Get the Stockscreener App
32.52
1.36%
-0.45
After Hours:
32.21
-0.31
-0.95%
Indivior Pharmaceuticals Inc stock is traded at $32.52, with a volume of 1.39M.
It is down -1.36% in the last 24 hours and up +4.53% over the past month.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
See More
Previous Close:
$32.97
Open:
$33
24h Volume:
1.39M
Relative Volume:
0.58
Market Cap:
$3.96B
Revenue:
$1.24B
Net Income/Loss:
$209.00M
P/E Ratio:
19.58
EPS:
1.6605
Net Cash Flow:
$-94.86M
1W Performance:
+1.82%
1M Performance:
+4.53%
6M Performance:
+29.10%
1Y Performance:
+256.97%
1-Day Range:
$32.13
$33.62
1-Week Range:
$30.11
$33.62
52-Week Range:
$8.69
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
32.52 | 4.02B | 1.24B | 209.00M | -94.86M | 1.6605 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
120.76 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.66 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.61 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
577.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
Assessing Indivior (INDV) Valuation After New SUBLOCADE Study In Correctional Healthcare - Sahm
Cipher Mining Stock, Five Below, Indivior Among 10 New Stocks On IBD Watchlists - Investor's Business Daily
A Look at Indivior Pharmaceuticals Inc (INDV) After 3.5% Gain -- GF Value $21.93 vs Price $31.60 - GuruFocus
Has The Strong Three-Year Run Left Indivior Pharmaceuticals (INDV) Priced Too Richly Today? - Yahoo Finance
How much upside is left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street analysts think 45.99% - MSN
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
Indivior Lends Voice to Help Raise Awareness of Substance Use Di - GuruFocus
If You Invested $1,000 in Indivior Pharmaceuticals Inc. (INDV) - Stock Titan
Indivior Pharmaceuticals Inc (INDV) Stock Down 5.5% but Still Overvalued -- GF Score: 72/100 - GuruFocus
Indivior Pharmaceuticals Inc (INDV) Stock Down 5.5% but Still Ov - GuruFocus
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results - TradingView — Track All Markets
Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV) - MSN
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 - TradingView — Track All Markets
How Much Upside is Left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street Analysts Think 45.99% - Yahoo Finance
Could Indivior (INDV) Turn Correctional Staffing Efficiencies Into a Durable Competitive Edge? - Sahm
Indivior to Report Q1 2026 Earnings, Host Webcast - National Today
Indivior to Report First Quarter 2026 Financial Results - National Today
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th - The Manila Times
Indivior investors get Q1 results at 7 a.m., webcast at 8 a.m. EDT - Stock Titan
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - TradingView — Track All Markets
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - zacks.com
INDV Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
INDV | Indivior Pharmaceuticals, Inc. Common Executive Compensation - Quiver Quantitative
INDV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
INDV Technical Analysis & Stock Price Forecast - Intellectia AI
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After New SUBLOCADE Cost Savings Evidence In Corrections Settings - Sahm
Indivior Pharmaceuticals Inc. R (E7P.F) Insider Ownership & Holdings - Yahoo! Finance Canada
JPMorgan Chase & Co. Has $5.01 Million Holdings in Indivior PLC $INDV - MarketBeat
Did Potential Jail Staffing Efficiencies From SUBLOCADE® Just Shift Indivior Pharmaceuticals' (INDV) Investment Narrative? - Sahm
Indivior Pharmaceuticals, Inc. (INDV) stock price, news, quote and history - Yahoo Finance UK
Small Cap Index Trust's Indivior Pharmaceuticals Inc(INDV) Holding History - GuruFocus
Indivior Pharmaceuticals Inc. R (E7P.F) Analyst Ratings, Estimates & Forecasts - Yahoo! Finance Canada
Indivior Pharmaceuticals, Inc. (INDV) Stock forecasts - Yahoo Finance UK
INDV Stock Price, Quote & Chart | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
What Indivior Pharmaceuticals (INDV)'s Prison Cost Model Findings Mean For Shareholders - Yahoo Finance
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - finance.yahoo.com
Suboxone Tooth Decay Lawsuit Settlement April 2026 Update - Lawsuit Information Center
Indivior Pharmaceuticals, Inc. (INDV) Options Chain - Yahoo! Finance Canada
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - theglobeandmail.com
Levi & Korsinsky Reminds Indivior Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024INDV - marketscreener.com
Indivior Pharmaceuticals, Inc - Reuters
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView — Track All Markets
New Cost Impact Model Highlights Potential Benefits of Monthly Injectable Buprenorphine - National Today
New Cost Model Shows Monthly Injectable Buprenorphine Can Reduce Staffing Burdens in Prisons - National Today
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities - The Manila Times
New Cost Impact Model Highlights Potential for Monthly - GlobeNewswire
Zacks.com spotlights Indivior, Ciena, and Ultra Clean as notable mentions - Bitget
Zacks.com featured highlights include Indivior, Ciena and Ultra Clean - Yahoo Finance
Indivior Pharmaceuticals Inc PE Ratio (TTM) & PE Ratio (TTM) ChartsINDV - GuruFocus
Indivior PLC (NASDAQ:INDV) Short Interest Up 21.7% in March - MarketBeat
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):